Capital Recovery Group, Federal Equipment Company, Heritage Global Partners, and PPL Group purchased a 110-acre campus with a flexible pharmaceutical manufacturing and packaging facility from a generics manufacturer in Huntsville, AL.
On Dec. 11, 2018, Capital Recovery Group (CRG), an international private equity firm based in Enfield, CT; Federal Equipment Company, a provider of used processing equipment based in Cleveland, OH; Heritage Global Partners, an industry auction company based in San Diego, CA; and PPL Group, a private equity firm based in Chicago, IL, announced the purchase of a flexible pharmaceutical manufacturing and packaging facility from a generics manufacturer in Huntsville, AL.
The companies report that a strategic redevelopment is planned for the 110-acre campus. This facility will accommodate a variety of uses ranging from the existing pharmaceutical, to alternate manufacturing, to high-cube distribution warehouse. The site includes three independent modern buildings: a distribution warehouse with offices, an oral solid dose facility with two serialized packaging lines, and a non-sterile liquids manufacturing facility with four filling lines. The site also has two pads for potential future expansion. Each of the three buildings and equipment are available as standalone operations or together.
“We are excited to share these opportunities, including bringing to market late-model tablet manufacturing and serialized packaging equipment, as well as offering top-quality liquids manufacturing and filling lines as a turnkey operation,” stated Adam Covitt, vice president of Federal Equipment Company, in a company press release.
Source: Federal Equipment Company
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.